Table 2. Study 2 Practice-Level Baseline Variables for Randomization

Practice-Level and Clinical Variables Obtained from EHR Data	Practice-Level Variables for Randomization (n = 18 Practices)		Differences Between Study Groups on Raw Variables^*
	Mean (SD)	Minimum, Maximum	Optimal Randomizations (n = 172)	Remaining Randomizations (n = 1556)
FTE clinicians (n)	3.8 (3.1)	1, 12	1.0 (2.6)	1.3 (3.2)^{^†}
African American race (%)	2.9 (3.7)	<1, 15.0	1.2 (3.1)	1.4 (3.1)^{^‡}
Hispanic ethnicity (%)	16.6 (18.5)	<1, 68.0	3.6 (10.7)	3.9 (10.7)
Medicaid/Uninsured (%)	13.8 (8.6)	0, 30.0	1.8 (3.3)	3.0 (7.5)^{^†}
Have type 2 diabetes (%)	34.9 (18.4)	13.0, 100	8.4 (15.3)	9.1 (16.8)^{^†}
HbA_1c >9 (%)	9.1 (7.5)	0, 25	1.5 (4.8)	2.4 (8.1)^{^†}
Stage 4 CKD (%)	6.7 (4.5)	0, 15.6	<1 (2.6)	1.9 (5.6)^{^†}
BP >130/80^{^§} (%)	58.1 (14.2)	35.4, 1.0	5.7 (14.4)	5.8 (18.0)^{^†}
BP>140/90 mmHg^{^‖} (%)	31.2 (11.6)	0, 51.9	2.6 (6.2)	4.5 (14.8)^{^†}
Mean HbA_1c^{^¶}	7.02 (0.38)	6.63, 7.88	0.05 (0.15)	0.12 ( 0.33)^{^†}
Mean eGFR	49.4 (3.2)	45.2, 59.4	0.7 (2.2)	1.3 (4.0)^{^†}
Mean systolic BP	132.1 (3.8)	124.7, 138.6	0.8 (2.5)	1.6 (5.1)^{^†}

↵* Data are means (maximums).
↵† P < .01, optimal vs. remaining randomizations.
↵‡ P < .05, optimal vs. remaining randomizations.
↵§ Patients have either systolic blood pressure (BP) >130 or diastolic BP >80, or both.
↵‖ Patients have either systolic BP >140 or diastolic BP >90, or both.
↵¶ Includes diabetic patients only.
CKD, chronic kidney disease; eGFR, estimate glomerular filtration rate; FTE, full-time equivalent; SD, standard deviation.